Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunoconjugates | 35 | 2024 | 951 | 10.360 |
Why?
|
Breast Neoplasms | 134 | 2024 | 20988 | 7.880 |
Why?
|
Camptothecin | 26 | 2024 | 591 | 6.030 |
Why?
|
Receptor, erbB-2 | 41 | 2024 | 2553 | 5.230 |
Why?
|
Cyclin-Dependent Kinase 4 | 25 | 2024 | 561 | 4.430 |
Why?
|
Receptors, Estrogen | 34 | 2024 | 2208 | 4.010 |
Why?
|
Cyclin-Dependent Kinase 6 | 17 | 2024 | 350 | 4.000 |
Why?
|
Estrogen Receptor alpha | 16 | 2024 | 583 | 3.580 |
Why?
|
Aminopyridines | 18 | 2024 | 573 | 3.300 |
Why?
|
Purines | 16 | 2024 | 606 | 2.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 44 | 2024 | 11735 | 2.710 |
Why?
|
Protein Kinase Inhibitors | 21 | 2024 | 5672 | 2.190 |
Why?
|
Antineoplastic Agents | 23 | 2024 | 13635 | 1.840 |
Why?
|
Neoplastic Cells, Circulating | 18 | 2024 | 943 | 1.820 |
Why?
|
Receptors, Progesterone | 12 | 2024 | 1129 | 1.720 |
Why?
|
Postmenopause | 15 | 2023 | 2511 | 1.720 |
Why?
|
Cell Adhesion Molecules | 10 | 2024 | 1602 | 1.660 |
Why?
|
Drug Resistance, Neoplasm | 21 | 2024 | 5304 | 1.600 |
Why?
|
Neoplasm Metastasis | 25 | 2024 | 4910 | 1.440 |
Why?
|
Aromatase Inhibitors | 14 | 2024 | 513 | 1.430 |
Why?
|
Antineoplastic Agents, Hormonal | 14 | 2024 | 1520 | 1.390 |
Why?
|
Antigens, Neoplasm | 12 | 2024 | 1985 | 1.250 |
Why?
|
Molecular Targeted Therapy | 13 | 2024 | 2812 | 1.150 |
Why?
|
Female | 172 | 2024 | 392203 | 1.090 |
Why?
|
Tetrahydronaphthalenes | 3 | 2022 | 86 | 1.080 |
Why?
|
Piperazines | 9 | 2024 | 2521 | 1.020 |
Why?
|
Androstadienes | 3 | 2021 | 348 | 0.950 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.910 |
Why?
|
Humans | 205 | 2024 | 760740 | 0.860 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 10 | 2024 | 899 | 0.830 |
Why?
|
Mutation | 25 | 2024 | 30015 | 0.790 |
Why?
|
Neoadjuvant Therapy | 11 | 2023 | 2827 | 0.770 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2019 | 257 | 0.750 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2024 | 9277 | 0.750 |
Why?
|
Pyridines | 6 | 2024 | 2875 | 0.730 |
Why?
|
Benzimidazoles | 3 | 2024 | 858 | 0.710 |
Why?
|
Breast Neoplasms, Male | 2 | 2024 | 212 | 0.690 |
Why?
|
Premenopause | 5 | 2021 | 1038 | 0.690 |
Why?
|
Chemotherapy, Adjuvant | 10 | 2020 | 3514 | 0.650 |
Why?
|
Estrogen Antagonists | 4 | 2023 | 150 | 0.650 |
Why?
|
Middle Aged | 79 | 2024 | 220603 | 0.630 |
Why?
|
Neutropenia | 4 | 2019 | 885 | 0.630 |
Why?
|
Aged | 65 | 2024 | 169092 | 0.620 |
Why?
|
BRCA2 Protein | 2 | 2020 | 797 | 0.620 |
Why?
|
Carcinoma, Lobular | 2 | 2022 | 480 | 0.620 |
Why?
|
Neoplasms | 22 | 2024 | 22131 | 0.610 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2018 | 99 | 0.600 |
Why?
|
Aspirin | 4 | 2020 | 3127 | 0.580 |
Why?
|
Androgen Receptor Antagonists | 1 | 2018 | 125 | 0.570 |
Why?
|
Tamoxifen | 6 | 2023 | 965 | 0.550 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1149 | 0.550 |
Why?
|
Morpholines | 1 | 2019 | 581 | 0.530 |
Why?
|
Clinical Trials as Topic | 14 | 2021 | 7995 | 0.520 |
Why?
|
Sex Ratio | 2 | 2006 | 107 | 0.490 |
Why?
|
Histone Deacetylases | 1 | 2019 | 719 | 0.470 |
Why?
|
Reproductive History | 1 | 2015 | 210 | 0.470 |
Why?
|
Cell Cycle | 4 | 2024 | 2929 | 0.470 |
Why?
|
Complementary Therapies | 3 | 2007 | 486 | 0.460 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2009 | 592 | 0.440 |
Why?
|
Chemoprevention | 1 | 2015 | 325 | 0.430 |
Why?
|
Standard of Care | 1 | 2017 | 551 | 0.430 |
Why?
|
Adult | 49 | 2024 | 220995 | 0.410 |
Why?
|
Breast | 3 | 2024 | 1963 | 0.400 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 4 | 2020 | 2270 | 0.400 |
Why?
|
Quality of Life | 10 | 2024 | 13359 | 0.390 |
Why?
|
Drug Substitution | 1 | 2014 | 290 | 0.380 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2019 | 2057 | 0.370 |
Why?
|
Aged, 80 and over | 23 | 2024 | 58919 | 0.370 |
Why?
|
Prognosis | 18 | 2024 | 29601 | 0.360 |
Why?
|
Antioxidants | 2 | 2009 | 1669 | 0.360 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2010 | 107 | 0.340 |
Why?
|
Selective Estrogen Receptor Modulators | 3 | 2024 | 131 | 0.340 |
Why?
|
Neoplasm Staging | 15 | 2021 | 11118 | 0.340 |
Why?
|
Phthalazines | 2 | 2024 | 383 | 0.340 |
Why?
|
Porphyria Cutanea Tarda | 1 | 2009 | 11 | 0.340 |
Why?
|
Bone Neoplasms | 2 | 2018 | 2527 | 0.330 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 629 | 0.320 |
Why?
|
Hot Flashes | 2 | 2009 | 330 | 0.320 |
Why?
|
Inguinal Canal | 1 | 2009 | 71 | 0.320 |
Why?
|
Cell Line, Tumor | 14 | 2024 | 16968 | 0.320 |
Why?
|
Iowa | 4 | 2015 | 104 | 0.300 |
Why?
|
Double-Blind Method | 8 | 2024 | 12333 | 0.290 |
Why?
|
Genotype | 6 | 2023 | 12977 | 0.290 |
Why?
|
Survival Rate | 8 | 2020 | 12719 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2021 | 3634 | 0.280 |
Why?
|
Infanticide | 1 | 2006 | 5 | 0.270 |
Why?
|
Moxibustion | 1 | 2006 | 8 | 0.270 |
Why?
|
Self Medication | 1 | 2007 | 117 | 0.270 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2019 | 10203 | 0.270 |
Why?
|
Disease-Free Survival | 7 | 2020 | 6807 | 0.260 |
Why?
|
Telemedicine | 1 | 2023 | 3051 | 0.260 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9171 | 0.260 |
Why?
|
Mediastinal Cyst | 1 | 2006 | 29 | 0.260 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2024 | 326 | 0.260 |
Why?
|
Tracheal Neoplasms | 1 | 2006 | 123 | 0.250 |
Why?
|
Pancreatic Pseudocyst | 1 | 2006 | 110 | 0.250 |
Why?
|
Proportional Hazards Models | 8 | 2021 | 12448 | 0.250 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2020 | 10754 | 0.250 |
Why?
|
Treatment Outcome | 24 | 2021 | 64572 | 0.250 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2007 | 361 | 0.250 |
Why?
|
Abdominal Abscess | 1 | 2007 | 153 | 0.250 |
Why?
|
Physicians, Family | 1 | 2007 | 348 | 0.250 |
Why?
|
Phytotherapy | 1 | 2007 | 296 | 0.240 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2023 | 2916 | 0.240 |
Why?
|
Primary Prevention | 1 | 2012 | 1185 | 0.240 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2020 | 410 | 0.240 |
Why?
|
Erythema | 1 | 2006 | 262 | 0.240 |
Why?
|
PTEN Phosphohydrolase | 2 | 2021 | 1113 | 0.230 |
Why?
|
Dietary Supplements | 2 | 2008 | 3412 | 0.230 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 106 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2022 | 2456 | 0.230 |
Why?
|
Receptors, Androgen | 3 | 2018 | 1079 | 0.220 |
Why?
|
Leiomyosarcoma | 1 | 2007 | 422 | 0.210 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5319 | 0.210 |
Why?
|
Lung Neoplasms | 7 | 2024 | 13383 | 0.210 |
Why?
|
Gene Expression Profiling | 2 | 2015 | 9417 | 0.210 |
Why?
|
Gene Expression | 1 | 2015 | 7569 | 0.200 |
Why?
|
Genomics | 6 | 2024 | 5822 | 0.200 |
Why?
|
Informed Consent | 2 | 2019 | 1007 | 0.200 |
Why?
|
Estrogen Receptor beta | 1 | 2023 | 168 | 0.200 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39062 | 0.200 |
Why?
|
Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2022 | 30 | 0.200 |
Why?
|
Anemia, Hemolytic | 1 | 2023 | 162 | 0.200 |
Why?
|
Biomedical Technology | 1 | 2004 | 210 | 0.200 |
Why?
|
Patient Care Planning | 1 | 2007 | 905 | 0.190 |
Why?
|
Carbolines | 1 | 2024 | 295 | 0.190 |
Why?
|
Neoplasm, Residual | 2 | 2024 | 1008 | 0.190 |
Why?
|
Patient Advocacy | 1 | 2024 | 360 | 0.190 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2023 | 147 | 0.190 |
Why?
|
Survival Analysis | 5 | 2021 | 10072 | 0.190 |
Why?
|
Colonic Neoplasms | 2 | 2011 | 2533 | 0.190 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2024 | 2863 | 0.190 |
Why?
|
Meningeal Carcinomatosis | 1 | 2021 | 63 | 0.190 |
Why?
|
Administration, Oral | 3 | 2024 | 4010 | 0.190 |
Why?
|
Receptors, Steroid | 2 | 2018 | 156 | 0.190 |
Why?
|
Nanotubes | 1 | 2021 | 82 | 0.180 |
Why?
|
Melanoma | 4 | 2007 | 5696 | 0.180 |
Why?
|
Information Storage and Retrieval | 1 | 2006 | 819 | 0.180 |
Why?
|
Mammography | 2 | 2021 | 2430 | 0.180 |
Why?
|
Acidosis, Lactic | 1 | 2022 | 146 | 0.180 |
Why?
|
Airway Obstruction | 1 | 2006 | 661 | 0.180 |
Why?
|
Medical Oncology | 3 | 2022 | 2317 | 0.180 |
Why?
|
Receptor, erbB-3 | 1 | 2021 | 143 | 0.180 |
Why?
|
Receptor, trkA | 1 | 2021 | 159 | 0.180 |
Why?
|
Inflammation Mediators | 1 | 2009 | 1884 | 0.180 |
Why?
|
Paclitaxel | 2 | 2018 | 1730 | 0.180 |
Why?
|
Review Literature as Topic | 1 | 2022 | 347 | 0.170 |
Why?
|
Nausea | 3 | 2021 | 679 | 0.170 |
Why?
|
Skin Neoplasms | 4 | 2007 | 5811 | 0.170 |
Why?
|
SEER Program | 3 | 2010 | 1450 | 0.170 |
Why?
|
Rectal Neoplasms | 1 | 2009 | 1156 | 0.170 |
Why?
|
Cell Separation | 3 | 2015 | 1718 | 0.170 |
Why?
|
Public Policy | 1 | 2004 | 557 | 0.170 |
Why?
|
Government Regulation | 1 | 2004 | 524 | 0.170 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4242 | 0.170 |
Why?
|
Health Care Surveys | 1 | 2007 | 2422 | 0.170 |
Why?
|
Anti-Inflammatory Agents | 1 | 2009 | 1810 | 0.170 |
Why?
|
Oxazepines | 1 | 2019 | 22 | 0.170 |
Why?
|
Cyclin-Dependent Kinases | 2 | 2021 | 655 | 0.160 |
Why?
|
Indazoles | 2 | 2021 | 304 | 0.160 |
Why?
|
Semaphorins | 1 | 2019 | 96 | 0.160 |
Why?
|
Gene Fusion | 2 | 2021 | 356 | 0.160 |
Why?
|
Body Weight | 3 | 2010 | 4615 | 0.160 |
Why?
|
International Agencies | 1 | 2019 | 242 | 0.160 |
Why?
|
Incidence | 7 | 2019 | 21339 | 0.160 |
Why?
|
Fluorouracil | 3 | 2020 | 1642 | 0.160 |
Why?
|
Age Factors | 4 | 2018 | 18381 | 0.160 |
Why?
|
Microfluidic Analytical Techniques | 2 | 2015 | 799 | 0.150 |
Why?
|
Glutathione Peroxidase | 1 | 2019 | 258 | 0.150 |
Why?
|
Evidence-Based Medicine | 2 | 2007 | 3680 | 0.150 |
Why?
|
Male | 35 | 2024 | 360402 | 0.150 |
Why?
|
Uterine Neoplasms | 1 | 2007 | 1420 | 0.150 |
Why?
|
Antiemetics | 2 | 2011 | 186 | 0.150 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 214 | 0.150 |
Why?
|
Ribosomal Proteins | 1 | 2020 | 370 | 0.150 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1700 | 0.140 |
Why?
|
Doxorubicin | 2 | 2018 | 2224 | 0.140 |
Why?
|
Cinnamates | 1 | 2016 | 59 | 0.140 |
Why?
|
Motor Activity | 1 | 2006 | 2714 | 0.140 |
Why?
|
Neuromuscular Diseases | 1 | 2019 | 258 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2021 | 1608 | 0.130 |
Why?
|
Pelvic Pain | 1 | 2018 | 292 | 0.130 |
Why?
|
Cardiovascular Diseases | 2 | 2012 | 15498 | 0.130 |
Why?
|
Vomiting | 2 | 2011 | 651 | 0.130 |
Why?
|
Disease Progression | 4 | 2023 | 13495 | 0.130 |
Why?
|
Acupuncture Therapy | 2 | 2013 | 486 | 0.130 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2020 | 825 | 0.130 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2018 | 506 | 0.130 |
Why?
|
Biomarkers, Pharmacological | 1 | 2016 | 161 | 0.130 |
Why?
|
Hepatitis C | 1 | 2006 | 1580 | 0.130 |
Why?
|
Forecasting | 2 | 2020 | 2924 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2020 | 8542 | 0.130 |
Why?
|
Adenocarcinoma | 2 | 2014 | 6345 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1404 | 0.130 |
Why?
|
Ligands | 1 | 2022 | 3268 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2020 | 802 | 0.130 |
Why?
|
Carpal Tunnel Syndrome | 1 | 2019 | 303 | 0.130 |
Why?
|
Cytomegalovirus | 1 | 2020 | 748 | 0.120 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2022 | 1084 | 0.120 |
Why?
|
Tumor Burden | 1 | 2021 | 1892 | 0.120 |
Why?
|
Acidosis, Renal Tubular | 2 | 2005 | 50 | 0.120 |
Why?
|
Prospective Studies | 10 | 2023 | 54364 | 0.120 |
Why?
|
Gene Amplification | 1 | 2019 | 1087 | 0.120 |
Why?
|
Back Pain | 1 | 2018 | 545 | 0.120 |
Why?
|
Clinical Protocols | 1 | 2020 | 1436 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 2913 | 0.120 |
Why?
|
Risk Factors | 12 | 2021 | 74128 | 0.120 |
Why?
|
Stomatitis | 1 | 2017 | 271 | 0.120 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2214 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 786 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2019 | 988 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2019 | 774 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2020 | 563 | 0.110 |
Why?
|
Biological Specimen Banks | 1 | 2019 | 778 | 0.110 |
Why?
|
Pyrazoles | 2 | 2021 | 2008 | 0.110 |
Why?
|
Europe | 1 | 2020 | 3415 | 0.110 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2006 | 2292 | 0.110 |
Why?
|
Leukocytes | 1 | 2021 | 2024 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4533 | 0.110 |
Why?
|
Imidazoles | 1 | 2019 | 1175 | 0.110 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2017 | 620 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 1 | 2007 | 3196 | 0.110 |
Why?
|
Retrospective Studies | 13 | 2023 | 80583 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 3599 | 0.110 |
Why?
|
Pilot Projects | 6 | 2023 | 8619 | 0.100 |
Why?
|
Drug Interactions | 1 | 2017 | 1415 | 0.100 |
Why?
|
Sulfonamides | 1 | 2022 | 1977 | 0.100 |
Why?
|
Meningeal Neoplasms | 1 | 2021 | 1245 | 0.100 |
Why?
|
Lymphedema | 1 | 2019 | 523 | 0.100 |
Why?
|
Retinoblastoma Protein | 1 | 2016 | 671 | 0.100 |
Why?
|
Musculoskeletal Diseases | 1 | 2018 | 597 | 0.100 |
Why?
|
Diarrhea | 1 | 2019 | 1317 | 0.100 |
Why?
|
Hospitals, General | 1 | 2016 | 798 | 0.100 |
Why?
|
Language | 1 | 2021 | 1541 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1422 | 0.100 |
Why?
|
Patient Preference | 1 | 2019 | 925 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2327 | 0.100 |
Why?
|
Antibodies | 1 | 2020 | 2413 | 0.100 |
Why?
|
Censuses | 2 | 2021 | 198 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4110 | 0.100 |
Why?
|
Data Mining | 1 | 2016 | 551 | 0.100 |
Why?
|
Animals | 16 | 2024 | 168202 | 0.090 |
Why?
|
Obesity | 3 | 2010 | 12934 | 0.090 |
Why?
|
Microfluidics | 2 | 2014 | 651 | 0.090 |
Why?
|
Signal Transduction | 5 | 2024 | 23415 | 0.090 |
Why?
|
Cisplatin | 1 | 2017 | 1650 | 0.090 |
Why?
|
Bone Density Conservation Agents | 1 | 2018 | 794 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2023 | 3599 | 0.090 |
Why?
|
Liver Neoplasms | 1 | 2006 | 4309 | 0.090 |
Why?
|
India | 3 | 2006 | 2286 | 0.090 |
Why?
|
Bone Diseases | 1 | 2013 | 418 | 0.090 |
Why?
|
Cohort Studies | 6 | 2021 | 41464 | 0.090 |
Why?
|
Syndrome | 2 | 2007 | 3268 | 0.090 |
Why?
|
Prostatic Neoplasms | 4 | 2015 | 11107 | 0.090 |
Why?
|
Exercise | 1 | 2006 | 5886 | 0.090 |
Why?
|
Carcinoma | 1 | 2021 | 2328 | 0.080 |
Why?
|
Nanostructures | 1 | 2015 | 551 | 0.080 |
Why?
|
Perimenopause | 2 | 2022 | 142 | 0.080 |
Why?
|
Anemia | 1 | 2019 | 1504 | 0.080 |
Why?
|
Muscular Diseases | 1 | 2013 | 552 | 0.080 |
Why?
|
Brain Neoplasms | 2 | 2021 | 9026 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 3027 | 0.080 |
Why?
|
Immunotherapy | 2 | 2023 | 4642 | 0.080 |
Why?
|
Sequence Analysis, RNA | 4 | 2020 | 2013 | 0.080 |
Why?
|
Patient Participation | 1 | 2018 | 1443 | 0.080 |
Why?
|
Antigens, CD | 1 | 2019 | 3998 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5334 | 0.080 |
Why?
|
RNA | 1 | 2018 | 2713 | 0.080 |
Why?
|
Ki-67 Antigen | 2 | 2023 | 627 | 0.080 |
Why?
|
Mitochondria | 1 | 2021 | 3619 | 0.080 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 407 | 0.080 |
Why?
|
Mice, Nude | 3 | 2019 | 3606 | 0.080 |
Why?
|
Leucovorin | 1 | 2010 | 643 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2013 | 737 | 0.070 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2014 | 937 | 0.070 |
Why?
|
Diphenhydramine | 1 | 2008 | 63 | 0.070 |
Why?
|
Echinacea | 1 | 2007 | 5 | 0.070 |
Why?
|
Ginkgo biloba | 1 | 2007 | 27 | 0.070 |
Why?
|
Anticarcinogenic Agents | 1 | 2009 | 249 | 0.070 |
Why?
|
Body Size | 1 | 2010 | 463 | 0.070 |
Why?
|
Young Adult | 5 | 2021 | 59191 | 0.070 |
Why?
|
Panax | 1 | 2007 | 28 | 0.070 |
Why?
|
Comorbidity | 2 | 2012 | 10507 | 0.070 |
Why?
|
Therapeutic Touch | 1 | 2006 | 9 | 0.070 |
Why?
|
Fatigue | 3 | 2022 | 1550 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3776 | 0.070 |
Why?
|
Lorazepam | 1 | 2008 | 155 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6483 | 0.070 |
Why?
|
Piracetam | 1 | 2007 | 88 | 0.070 |
Why?
|
Medical Subject Headings | 1 | 2006 | 16 | 0.070 |
Why?
|
Cholestasis, Intrahepatic | 1 | 2007 | 75 | 0.070 |
Why?
|
Massage | 1 | 2006 | 86 | 0.070 |
Why?
|
Drug Approval | 1 | 2013 | 812 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3868 | 0.070 |
Why?
|
Publication Bias | 1 | 2007 | 160 | 0.070 |
Why?
|
Recurrence | 2 | 2017 | 8426 | 0.070 |
Why?
|
Fingers | 1 | 2009 | 506 | 0.070 |
Why?
|
Biopsy | 1 | 2018 | 6763 | 0.070 |
Why?
|
Haloperidol | 1 | 2008 | 389 | 0.070 |
Why?
|
Nootropic Agents | 1 | 2007 | 157 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4570 | 0.070 |
Why?
|
Tumor Cells, Cultured | 3 | 2019 | 6126 | 0.070 |
Why?
|
Sphincterotomy, Endoscopic | 1 | 2006 | 44 | 0.070 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2009 | 489 | 0.060 |
Why?
|
PubMed | 1 | 2006 | 129 | 0.060 |
Why?
|
Genetic Testing | 1 | 2019 | 3533 | 0.060 |
Why?
|
Databases, Factual | 2 | 2018 | 7963 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3873 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2013 | 1661 | 0.060 |
Why?
|
Inpatients | 3 | 2021 | 2545 | 0.060 |
Why?
|
Hypophosphatemia, Familial | 1 | 2005 | 32 | 0.060 |
Why?
|
Sex Determination Analysis | 1 | 2004 | 46 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 23974 | 0.060 |
Why?
|
Abortion, Eugenic | 1 | 2004 | 39 | 0.060 |
Why?
|
Stroke Volume | 1 | 2018 | 5486 | 0.060 |
Why?
|
Pulmonary Ventilation | 1 | 2006 | 372 | 0.060 |
Why?
|
Rickets | 1 | 2005 | 70 | 0.060 |
Why?
|
Mice | 10 | 2021 | 81368 | 0.060 |
Why?
|
Diet, Fat-Restricted | 1 | 2007 | 329 | 0.060 |
Why?
|
Goserelin | 1 | 2024 | 126 | 0.060 |
Why?
|
United States | 5 | 2013 | 72292 | 0.060 |
Why?
|
Mind-Body Therapies | 1 | 2006 | 279 | 0.050 |
Why?
|
Registries | 2 | 2017 | 8209 | 0.050 |
Why?
|
Anti-Obesity Agents | 1 | 2007 | 227 | 0.050 |
Why?
|
Medical Staff, Hospital | 1 | 2007 | 601 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2020 | 2010 | 0.050 |
Why?
|
Mice, Inbred NOD | 2 | 2019 | 1827 | 0.050 |
Why?
|
Taxoids | 1 | 2006 | 667 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3426 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2019 | 10429 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
Prevalence | 2 | 2019 | 15702 | 0.050 |
Why?
|
Physical Fitness | 1 | 2006 | 743 | 0.050 |
Why?
|
DNA Copy Number Variations | 2 | 2022 | 2020 | 0.050 |
Why?
|
Foot | 1 | 2006 | 575 | 0.050 |
Why?
|
Mice, SCID | 2 | 2019 | 2625 | 0.050 |
Why?
|
Medical Records | 1 | 2007 | 1408 | 0.050 |
Why?
|
Survivors | 1 | 2012 | 2373 | 0.050 |
Why?
|
Transcription Factors | 1 | 2021 | 12116 | 0.050 |
Why?
|
Physical Examination | 1 | 2007 | 1254 | 0.050 |
Why?
|
Family Characteristics | 1 | 2006 | 992 | 0.050 |
Why?
|
Anorexia | 1 | 2021 | 154 | 0.050 |
Why?
|
Laryngoscopy | 1 | 2006 | 707 | 0.050 |
Why?
|
Hemolysis | 1 | 2023 | 415 | 0.050 |
Why?
|
Drug Delivery Systems | 2 | 2009 | 2222 | 0.050 |
Why?
|
Hand | 1 | 2006 | 902 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2007 | 1315 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Single-Cell Analysis | 3 | 2018 | 2447 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2007 | 1070 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2006 | 2218 | 0.040 |
Why?
|
RNA, Neoplasm | 2 | 2013 | 749 | 0.040 |
Why?
|
Hepatitis | 1 | 2021 | 228 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4845 | 0.040 |
Why?
|
Pain | 2 | 2022 | 5062 | 0.040 |
Why?
|
Annexin A6 | 1 | 2018 | 4 | 0.040 |
Why?
|
Body Mass Index | 3 | 2021 | 12942 | 0.040 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2007 | 955 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2016 | 4810 | 0.040 |
Why?
|
Sleep Apnea Syndromes | 1 | 2007 | 978 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15250 | 0.040 |
Why?
|
Internet | 1 | 2011 | 3094 | 0.040 |
Why?
|
Pancreatitis | 1 | 2006 | 1097 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 596 | 0.040 |
Why?
|
Naphthalenes | 1 | 2019 | 198 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 413 | 0.040 |
Why?
|
Ultrasonography, Prenatal | 1 | 2006 | 1754 | 0.040 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2024 | 1148 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 849 | 0.040 |
Why?
|
Adolescent | 2 | 2021 | 88247 | 0.040 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.040 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 391 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2017 | 205 | 0.040 |
Why?
|
Cyclin D1 | 1 | 2019 | 451 | 0.030 |
Why?
|
Phenotype | 2 | 2016 | 16572 | 0.030 |
Why?
|
Thiazoles | 1 | 2024 | 1517 | 0.030 |
Why?
|
Quinoxalines | 1 | 2019 | 296 | 0.030 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.030 |
Why?
|
Glucuronosyltransferase | 1 | 2017 | 132 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2004 | 2697 | 0.030 |
Why?
|
Social Support | 1 | 2006 | 2174 | 0.030 |
Why?
|
Bariatric Surgery | 1 | 2007 | 992 | 0.030 |
Why?
|
Abdominal Neoplasms | 1 | 2018 | 287 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2018 | 602 | 0.030 |
Why?
|
Models, Statistical | 1 | 2011 | 5074 | 0.030 |
Why?
|
Half-Life | 1 | 2017 | 650 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 634 | 0.030 |
Why?
|
Immunomodulation | 1 | 2020 | 548 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2021 | 974 | 0.030 |
Why?
|
Benzamides | 1 | 2021 | 1371 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 994 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2017 | 385 | 0.030 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2017 | 287 | 0.030 |
Why?
|
gamma Catenin | 1 | 2014 | 44 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 12966 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1521 | 0.030 |
Why?
|
Skin | 1 | 2008 | 4472 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9461 | 0.030 |
Why?
|
Fever | 1 | 2021 | 1618 | 0.030 |
Why?
|
Primary Health Care | 2 | 2007 | 4677 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1626 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 917 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 496 | 0.030 |
Why?
|
Quinolines | 1 | 2019 | 764 | 0.030 |
Why?
|
Ultrasonography | 1 | 2007 | 5965 | 0.030 |
Why?
|
Apoptosis | 2 | 2019 | 9476 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10549 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2020 | 1348 | 0.030 |
Why?
|
Diphosphonates | 1 | 2018 | 635 | 0.030 |
Why?
|
Gelatin | 1 | 2015 | 220 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2019 | 2509 | 0.030 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 1027 | 0.030 |
Why?
|
Colitis | 1 | 2021 | 1234 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2018 | 1088 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1000 | 0.030 |
Why?
|
Glutarates | 1 | 2014 | 243 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 2022 | 1419 | 0.030 |
Why?
|
Pyridones | 1 | 2017 | 808 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5239 | 0.020 |
Why?
|
Cell Shape | 1 | 2013 | 369 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 22117 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2014 | 717 | 0.020 |
Why?
|
Materials Testing | 1 | 2015 | 863 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14649 | 0.020 |
Why?
|
Hospitalization | 2 | 2021 | 10708 | 0.020 |
Why?
|
Cell Size | 1 | 2013 | 624 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1088 | 0.020 |
Why?
|
Vitamin D | 1 | 2005 | 3301 | 0.020 |
Why?
|
Pandemics | 2 | 2021 | 8652 | 0.020 |
Why?
|
Base Sequence | 1 | 2021 | 12420 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 6927 | 0.020 |
Why?
|
Culture | 1 | 2014 | 623 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2023 | 18220 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1467 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3593 | 0.020 |
Why?
|
Molecular Imaging | 1 | 2016 | 814 | 0.020 |
Why?
|
Mesoderm | 1 | 2013 | 674 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20077 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2015 | 1118 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2015 | 1674 | 0.020 |
Why?
|
Estradiol | 1 | 2016 | 1937 | 0.020 |
Why?
|
Inflammation | 1 | 2009 | 10759 | 0.020 |
Why?
|
Research Design | 2 | 2020 | 6174 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2515 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2010 | 518 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2020 | 5463 | 0.020 |
Why?
|
Cell Count | 1 | 2013 | 1834 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2019 | 3115 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2019 | 26065 | 0.020 |
Why?
|
Aging | 1 | 2007 | 8700 | 0.020 |
Why?
|
Temperature | 1 | 2015 | 2224 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8835 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3743 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6593 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6473 | 0.020 |
Why?
|
Gene Frequency | 1 | 2014 | 3601 | 0.020 |
Why?
|
Internship and Residency | 1 | 2007 | 5878 | 0.020 |
Why?
|
DNA Damage | 1 | 2017 | 2445 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2014 | 1662 | 0.020 |
Why?
|
Equipment Design | 1 | 2015 | 3501 | 0.020 |
Why?
|
Gels | 1 | 2008 | 420 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2015 | 1683 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9526 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2006 | 26183 | 0.020 |
Why?
|
Odds Ratio | 1 | 2018 | 9644 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2008 | 712 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 1962 | 0.020 |
Why?
|
Bone Density | 1 | 2018 | 3548 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5780 | 0.010 |
Why?
|
Child | 3 | 2008 | 80089 | 0.010 |
Why?
|
Dizziness | 1 | 2007 | 259 | 0.010 |
Why?
|
Pregnancy | 1 | 2006 | 29869 | 0.010 |
Why?
|
Bibliometrics | 1 | 2007 | 352 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2018 | 14388 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4739 | 0.010 |
Why?
|
Sleep Stages | 1 | 2007 | 695 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2006 | 20556 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2015 | 3567 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11069 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2013 | 3672 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5201 | 0.010 |
Why?
|
Population Surveillance | 1 | 2011 | 2597 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2007 | 1110 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2011 | 2768 | 0.010 |
Why?
|
Exercise Therapy | 1 | 2007 | 929 | 0.010 |
Why?
|
Creatinine | 1 | 2005 | 1895 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7583 | 0.010 |
Why?
|
Body Height | 1 | 2005 | 1565 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2007 | 1463 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2007 | 3461 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 39908 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 8516 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2007 | 3451 | 0.010 |
Why?
|
Feeding Behavior | 1 | 2007 | 3183 | 0.010 |
Why?
|
Infant | 2 | 2005 | 36157 | 0.010 |
Why?
|
Child, Preschool | 2 | 2005 | 42193 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 12043 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2007 | 15829 | 0.010 |
Why?
|